Unsubscribed Membership

The membership has expired or been canceled by subscriber

The numbers I like the most are the ones that compound ... Albert Einstein, Physicist

    • Oops!
      The Members Area Requires a Current Subscription

      It appears the membership has expired. You can RENEW immediately by clicking on the button below. If you are a NEW USER, then kindly visit the Newsletters section on the menu above to Sign Up. If you have an active paid membership and facing login issues, kindly send an email to support@ GraycellAdvisors. com (remove spaces if you copy the email).

    Renew Now(you can choose time period on next screen)

    The Graycell Small Cap Portfolio focuses on the universe of stocks from $200 million to $3 billion in market capitalization. The portfolio investment focus is to participate in the early stages of the growth of a company while diversifying sufficiently across a market cap range that includes even early stage midcap or SMID companies. The return objective of the quantitative model driven portfolio is to outperform the Russell 2000 by at least 5% points over a 12-month period. As you will observe from the long history, the model portfolio performance has surpassed its objective quite convincingly. The model portfolio comprises up to 10 stocks, which are nearly equally-weighted.

    Graycell Advisors, and its affiliates, officers, employees, families, and all other related parties, collectively referred to as ‘Graycell’ and/or ‘we,’ is a publisher of financial information, such as the Smallcap, and Prudent Biotech newsletters. We are not a Registered Investment Advisor (RIA). Historical performance figures provided are hypothetical and unaudited, and based on our proprietary analysis and system performance, back-tested over an extended period of time. Hypothetical or simulated performance results have limitations, and unlike an actual performance record, simulated results do not represent actual trading and consequently do not involve financial risk of actual trading. The performance results obtained are intended for illustrative purposes only. No representation is being made that an account will or is likely to achieve profit or losses similar to those shown. Past performance is not indicative of future results, which may vary. All stock and related investments have a degree of risk, which can result in a significant or total loss. In addition, biotech sector and smallcaps are characterized by much higher risk and volatility than the general stock market. Information contained herein is general and does not constitute a personal recommendation or takes into account the particular investment objectives, financial situations, or needs of individual investors. If you decide to invest in any of the stocks of the companies mentioned in the newsletters, samples, alerts, etc., sent to you or available on our websites, you can and may lose some or all of your investment. You alone are responsible for your investment decisions. Use of the information herein is at one's own risk. We are simply sharing the results of our model. Nothing should be construed as a recommendation or an offer to buy or sell any securities, and we are not liable nor do we assume any liability or responsibility for losses incurred as a result of any information provided or not provided or not made available in a timely manner, herein or on our website or using any other medium. We cannot guarantee the accuracy and completeness of any information furnished by us. We may or may not have existing positions in the stocks mentioned in our reports. Our models are proprietary and/or licensed, and can be changed or revised based on our discretion at any time without any notification. Subscribers and investors should always conduct their own due diligence with any potential investment, and consider obtaining professional advice before making an investment decision.
    © Graycell Advisors. All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the written permission of Graycell Advisors is strictly prohibited and shall be deemed to be copyright infringement.